Rigel Pharmaceutical Inc. buy tamam
Start price
18.04.17
/
50%
€2.93
Target price
22.05.17
€3.61
Performance (%)
-21.85%
End price
22.05.17
€2.29
Summary
This prediction ended on 22.05.17 with a price of €2.29. The price of Rigel Pharmaceutical Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -21.85%. tamam has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Rigel Pharmaceutical Inc. | 8.019% | 8.019% | -30.737% | -71.230% |
iShares Core DAX® | -1.226% | 2.804% | 14.933% | 16.561% |
iShares Nasdaq 100 | -1.845% | 2.732% | 26.075% | 54.743% |
iShares Nikkei 225® | -1.132% | -2.218% | 5.361% | 4.560% |
iShares S&P 500 | -0.980% | 1.883% | 22.727% | 45.760% |
Comments by tamam for this prediction
In the thread Rigel Pharmaceutical Inc. diskutieren
Rigel Pharmaceuticals (NASDAQ:RIGL) submits a New Drug Application
- to the FDA seeking approval of fostamatinib for the treatment of
patients with chronic and persistent immune thrombocytopenia (ITP), an Orphan Drug indication.
- Fostamatinib inhibits an enzyme called spleen tyrosine kinase (SYK) which plays a key role in certain blood cancers and autoimmune disorders.
(Vom Mitglied beendet)